Gilead Sciences Drug Wins FDA Approval in Most Common Type of Breast Cancer Gilead Sciences drug Trodelvy is now approved for treating patients whose breast cancer is classified as HR positive and HER2 negative, expanding use of the drug to a much wider group of patients. In other regulatory approval news, use of Takeda Pharmaceutical’s…